Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) is now available.
Sihuan Pharmaceutical Holdings Group announced that its non-wholly-owned subsidiary Xuanzhu Biopharm has received notification from the CSRC confirming completion of filing for the conversion of 357,245,794 unlisted shares into the same number of H shares. Subject to final implementation details, regulatory procedures and approval from the Hong Kong Stock Exchange, these converted H shares will be listed and traded on the Main Board within the approval’s validity period.
The move towards H share full circulation is expected to enhance the liquidity and market visibility of Xuanzhu Biopharm, potentially broadening its investor base and supporting capital market access for its innovation-driven drug pipeline. Both Sihuan Pharmaceutical and Xuanzhu Biopharm cautioned shareholders and potential investors that the conversion and listing remain contingent on further regulatory steps, and that detailed implementation arrangements will be announced in due course in line with listing and disclosure requirements.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group is an international medical aesthetic and pharmaceutical company founded in 2001 and listed in Hong Kong since 2010. The group operates an innovation-led model with a broad global product pipeline, strong registration capabilities, cost-efficient multi-dosage manufacturing, and a mature sales network, aiming to become a leading medical aesthetics and biopharmaceutical player in China through a two-wheel drive strategy.
Xuanzhu Biopharm, a non-wholly-owned subsidiary of Sihuan Pharmaceutical, is an innovative drug developer rooted in China with a global outlook. It focuses on major diseases such as digestive disorders, oncology and non-alcoholic steatohepatitis, leveraging dual R&D platforms in small molecules and large molecule biopharmaceuticals, including ADCs, to build a pipeline of class 1 drugs with proprietary intellectual property and integrated R&D, production and commercialization capabilities.
YTD Price Performance: 16.26%
Average Trading Volume: 35,817,131
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$13.34B
For a thorough assessment of 0460 stock, go to TipRanks’ Stock Analysis page.